The Walt Disney Company (NYSE:DIS) delivered second-quarter 2026 results that modestly exceeded its previous operating income guidance, fueled by robust revenue growth across its media and experiences portfolios.
Louisiana-Pacific (NYSE:LPX) reported a challenging start to 2026, as the company grappled with a broad-based slowdown across its primary building product categories.
Clear Channel Outdoor Holdings (NYSE:CCO) reported double-digit revenue growth for the first quarter of 2026, a performance that arrives amid significant corporate restructuring.
Flowco Holdings (NYSE:FLOC), a leading provider of production optimization and emissions management solutions, announced first-quarter 2026 results that underscore the company’s increasing scale within the oil and natural gas services sector.
Northwest Natural Holding Company (NYSE:NWN) delivered a robust start to 2026, reporting increased earnings and a steady expansion of its gas and water utility footprint.
Owens Corning (NYSE:OC) reported first-quarter 2026 financial results that reflected a cooling in the global building products market.
FuboTV (NYSE:FUBO) reported second-quarter 2026 financial results that underscore the massive scale achieved through its recent business combination with Hulu + Live TV.
BeOne Medicines (NASDAQ:ONC) delivered a record-breaking first quarter for 2026, as the global oncology specialist saw its flagship therapy, Brukinsa (zanubrutinib), cement its status as a leading treatment in the BTK inhibitor market.
Oscar Health (NYSE:OSCR) delivered a record-breaking first quarter for 2026, posting a surge in net income and membership that indicates its "reset" strategy has taken firm root.
LivaNova (NASDAQ:LIVN) delivered a robust first-quarter performance for 2026, characterized by double-digit revenue growth and a major regulatory win in the sleep apnea market.
Novo Nordisk (NYSE:NVO) reported a landmark start to 2026, headlined by the historic commercial debut of the Wegovy pill in the United States.
Novavax (NASDAQ:NVAX) reported a significant contraction in top-line results for the first quarter of 2026, reflecting the company’s ongoing transition from a high-volume manufacturer to a leaner, research-and-licensing-focused biotechnology entity.
